Izalontamab Brengitecan

Izalontamab Brengitecan injection in India
Generic Name/API:Izalontamab Brengitecan
Storage:Store refrigerated at 2°C–8°C. Protect from light. Do not freeze. Store and transport according to cold-chain requirements.
Dosage:For dosage information, please visit the General Information section.
Strength:120 mg per single-use vial.
Indication:It is indicated for adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have failed at least two prior systemic therapies, including platinum-based chemotherapy and PD-1/PD-L1 inhibitors, as well as adult patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) whose disease has progressed following treatment with a PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy.

Izalontamab Brengitecan is a potential first-in-class bispecific antibody-drug conjugate (ADC) which targets both epidermal growth factor receptor and human epidermal growth factor receptor 3 (EGFRxHER3) with a topoisomerase 1 inhibitor payload..

It binds simultaneously to epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and uses a cleavable linker to release a topoisomerase I inhibitor payload inside the tumor cell.The payload then stops DNA replication, causing cell cycle arrest and apoptosis (programmed cell death).

Strength:

120 mg per single-use vial.

Dosage: 

2.5 mg/kg once per day on days 1 and 8 of every 3-week cycle.

Adverse Reactions:

Common Adverse Reactions: The most commonly reported adverse reactions include fatigue, nausea, decreased appetite, anemia, neutropenia, thrombocytopenia, elevated liver enzymes, diarrhea, and infusion-related reactions.

Serious Adverse Reactions: Serious adverse reactions may include severe infusion-related reactions, severe neutropenia, serious infections, hepatotoxicity, and interstitial lung disease (ILD)/pneumonitis. Patients should be closely monitored throughout treatment and managed according to clinical guidelines.

Storage: 

Store refrigerated at 2°C–8°C. Protect from light. Do not freeze. Store and transport according to cold-chain requirements.

  • Severe Myelosuppression (Hematologic Toxicity): Treatment frequently causes grade 3 or higher decreases in blood cell counts. Prevalent complications include decreased neutrophil count (neutropenia), low white blood cell count (leukopenia), decreased platelet count (thrombocytopenia), and anemia.
  • Gastrointestinal Toxicities: Severe stomatitis (mouth inflammation) and gastrointestinal adverse events are common during therapy and require monitoring.
  • Interstitial Lung Disease (ILD) / Pneumonitis: Cases of interstitial lung disease and pneumonitis have been reported in clinical trials. Patients with a prior history of ILD or active pneumonitis are typically excluded from administration.
  • Embryo-Fetal Toxicity (Teratogenicity): Preclinical and clinical protocol policies indicate that izalontamab brengitecan is teratogenic. Women of childbearing potential and male patients must use highly effective contraception during treatment and for a defined washout period following the last dose (typically 7 months for women and 4 months for men).

Process to Import Medicine

FAQ

Izalontamab brengitecan is a bispecific ADC targeting EGFR and HER3, designed to deliver a topoisomerase I inhibitor payload to tumor cells.

It simultaneously targets EGFR and HER3, two receptors involved in tumor growth and survival signaling.

It is a bispecific antibody-drug conjugate (ADC).

According to the provided August 2026 source, Iza-Bren has received approval in China for specified previously treated patients with recurrent or metastatic NPC and ESCC. It is not yet broadly approved in other markets.

A 2.5 mg/kg IV dose on Days 1 and 8 of a 21-day cycle has been used as the recommended Phase II dose in clinical development.

The price of Izalontamab Brengitecan in India may vary depending on currency fluctuations and import duties. For the latest pricing details, contact 247QualityMeds at +91-9967979080.

To buy Izalontamab Brengitecan injection in India, a valid prescription is required. Contact 247QualityMeds to enquire about medicine availability and proceed with the prescription-based procurement process.

To Buy Izalontamab Brengitecan in Delhi, contact 247QualityMeds with a valid prescription. Our team can assist with the prescription-based process and provide information on medicine availability.

Related products